Alemtuzumab in treatment of chronic lymphocytic leukemia

Efficiency of alemtuzumab (Campath) in 8 patients with chronic lymphocytic leukemia (CLL) was reported. Patients treated with alemtuzumab or alemtuzumab in combination with fludarabine (FluCam). Therapy response, overall survival and incidence of side effects were estimated. Among 5 patients with pr...

Full description

Saved in:
Bibliographic Details
Published inOnkogematologii͡a no. 3; pp. 15 - 22
Main Authors S. S. Bessmeltsev, E. V. Litvinskaya, K. M. Abdulkadirov, E. V. Karyagina
Format Journal Article
LanguageRussian
Published ABV-press 01.11.2022
Subjects
alemtuzumab
chronic lymphoid leukemia
complete remission
Online AccessGet full text

Cover

More Information
Summary:Efficiency of alemtuzumab (Campath) in 8 patients with chronic lymphocytic leukemia (CLL) was reported. Patients treated with alemtuzumab or alemtuzumab in combination with fludarabine (FluCam). Therapy response, overall survival and incidence of side effects were estimated. Among 5 patients with primary CLL, therapy response was 100%. Alemtuzumab was high effective in patients with relapsed and refractory CLL too. The main complications were myelosupression and infections. High efficacy of alemtuzumab in CLL therapy was shown.
ISSN:1818-8346
2413-4023
DOI:10.17650/1818-8346-2009-0-3-15-22